Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: Studies on amitriptyline as a model substrate

Journal of Pharmacology and Experimental Therapeutics

Volumn 297, Issue 1, 2001, Pages 326-337

  Venkatakrishnan, K ^a   Von Moltke, L L ^a   Greenblatt, D J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CYTOCHROME P450;

ARTICLE; BASAL METABOLIC RATE; BIOTRANSFORMATION; CATALYSIS; DEMETHYLATION; DRUG EFFECT; ENZYME KINETICS; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; LIVER MICROSOME; LYMPHOBLAST; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMITRIPTYLINE; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; KETOCONAZOLE; MICROSOMES, LIVER; PHENOTYPE; RECOMBINANT PROTEINS;

EID: 0035079928     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes
2. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans
3. In vitro assessment of human cytochrome P450
4. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research
5. The use of heterologously expressed drug metabolizing enzymes - State of the art and prospects for the future
6. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions
7. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
8. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model
9. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide
10. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport
11. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms
12. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: A study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs
13. Nonspecific binding of drugs to human liver microsomes
14. Amitriptyline metabolism: Relationship to polymorphic debrisoquine hydroxylation
15. Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers
16. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
17. In vitro metabolism of quinidine: The (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes
18. The prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of the in vitro half-life approach and nonspecific binding to microsomes
19. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
20. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes
21. Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes
22. Interindividual differences in amitriptyline demethylation
23. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles
24. Enzyme kinetic modeling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: Application to amitriptyline N-demethylation
25. N-demethylation of amitriptyline in vitro: Role of cytochrome P-450 3A (CYP3A) isoforms, and effect of metabolic inhibitors
26. Discrepancies between pharmacokinetic studies of amitriptyline
27. Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes
28. Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism
29. Scaling drug biotransformation data cDNA-expressed CYP to human liver: A comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism
30. Enzyme-catalyzed processes of firstpass hepatic and intestinal drug extraction
31. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: Dominance of CYP 2C19 and 3A4
32. Comparison between CYP content and relative activity approaches to scaling from cDNA-expressed cytochromes P450 to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches
33. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach
34. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low-affinity): Implications for interactions with enzyme-inducing drugs
35. Microsomal binding of amitriptyline: Effect on estimation of enzyme kinetic parameters in vitro
36. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo
37. Alprazolam metabolism in vitro: Studies of human, monkey, mouse, and rat liver microsomes
38. In vitro approaches to predicting drug interactions in vivo
39. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples